P&G Joins Novartis’ Efforts To Market Overactive Bladder Treatment Enablex
This article was originally published in The Pink Sheet Daily
Executive Summary
Co-promotion agreement leaves the door open for P&G and Novartis to solicit FDA for approval of Enablex as OTC. Deal brings expanded sales force in a crowded market.
You may also be interested in...
Sanctura Once-Daily NDA Touts “Landmark Tolerability”
Indevus will position the XR version of its incontinence therapy based on its low incidence of dry mouth.
Sanctura Once-Daily NDA Touts “Landmark Tolerability”
Indevus will position the XR version of its incontinence therapy based on its low incidence of dry mouth.
Sanctura Co-Promotion Deal
Esprit Pharma has become Indevus' new co-promotion partner for Sanctura (trospium), after acquiring marketing rights for the overactive bladder agent from Pliva